60
603811.SHG Zhejiang Cheng Yi Pharmaceutical Co Ltd
- Market cap
- CNY 3.10B
- P/E
- 16.5x
- P/B
- 2.08x
- ROE
- 12.2%
- Dividend yield
- 2.69%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603811.SHG undervalued?
Graham number603811.SHG trades 23.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Cheng Yi Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Cheng Yi Pharmaceutical Co Ltd yet.
Zhejiang Cheng Yi Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Cheng Yi Pharmaceutical Co Ltd
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. engages in the research, development, production, and sales of formulations and active pharmaceutical ingredients in China and internationally. The company offers glucosamine hydrochloride raw materials and preparations, gastrodin raw materials, ribavirin preparations raw materials, and sulfur dioxide raw materials. It also provides injections, food, capsules, tablets, traditional Chinese medicines, preparations, and intermediates; …
Full company profileZhejiang Cheng Yi Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Cheng Yi Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 321M | 341M | 546M | 681M | 758M | 694M | 655M | 672M | 714M | 812M | 819M |
| Gross Profit | 160M | 173M | 349M | 493M | 552M | 485M | 437M | 423M | 489M | 567M | 583M |
| Operating Income | 76.0M | 78.8M | 113M | 154M | 190M | 199M | 164M | 174M | 221M | 186M | 185M |
| EBITDA | 95.6M | 98.5M | 133M | 176M | 242M | 258M | 235M | 267M | 324M | 322M | 199M |
| Net Income | 68.2M | 69.2M | 96.9M | 131M | 165M | 171M | 162M | 163M | 201M | 195M | 182M |
| EPS | 0.28 | 0.23 | 0.30 | 0.40 | 0.51 | 0.52 | 0.49 | 0.50 | 0.61 | 0.43 | 0.40 |
| Balance Sheet | |||||||||||
| Total Assets | 364M | 673M | 816M | 980M | 1.21B | 1.32B | 1.72B | 1.89B | 1.73B | 1.70B | 1.78B |
| Total Liabilities | 84.1M | 73.4M | 142M | 211M | 321M | 324M | 628M | 696M | 463M | 305M | 275M |
| Shareholders' Equity | 280M | 600M | 661M | 757M | 874M | 986M | 1.09B | 1.19B | 1.26B | 1.39B | 1.49B |
| Cash & Short-term Investments | 78.2M | 73.7M | 178M | 141M | 72.3M | 83.3M | 214M | 294M | 173M | 221M | 191M |
| Total Debt | 12.0M | - | 12.6M | 10.0M | 120M | 149M | 427M | 444M | 190M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 95.1M | 66.8M | 134M | 181M | 178M | 143M | 166M | 195M | 206M | 280M | - |
| Capital Expenditure | 21.6M | 38.0M | 272M | 184M | 144M | 134M | 253M | 70.9M | 59.9M | 45.4M | 81.9M |
| Free Cash Flow | 73.4M | 28.8M | -137M | -2.80M | 34.1M | 9.38M | -86.9M | 124M | 146M | 235M | 163M |
| Ratios | |||||||||||
| ROE | 24.3% | 11.5% | 14.7% | 17.4% | 18.9% | 17.3% | 14.9% | 13.7% | 15.9% | 14.0% | 12.2% |
| ROA | 18.7% | 10.3% | 11.9% | 13.4% | 13.7% | 12.9% | 9.4% | 8.6% | 11.6% | 11.5% | 10.3% |
| Net Profit Margin | 21.2% | 20.3% | 17.8% | 19.3% | 21.8% | 24.6% | 24.7% | 24.3% | 28.1% | 24.0% | 22.3% |
| Debt to Equity | 0.04x | - | 0.02x | 0.01x | 0.14x | 0.15x | 0.39x | 0.37x | 0.15x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Cheng Yi Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.69%
- Forward dividend
- 0.30 CNY
- Payout ratio
- 42.8%
- Ex-dividend date
- Jun 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 83.5M | 0.18 | 42.8% |
| 2024 | CNY 76.7M | 0.23 | 38.2% |
| 2023 | CNY 73.9M | 0.23 | 45.4% |
| 2022 | CNY 58.4M | 0.18 | 36.2% |
| 2021 | CNY 58.4M | 0.18 | 34.2% |
| 2020 | CNY 47.7M | 0.15 | 28.9% |
| 2019 | CNY 35.8M | 0.11 | 27.2% |
| 2018 | CNY 35.9M | 0.11 | 37.0% |
| 2017 | CNY 35.3M | 0.12 | 51.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 26, 2026.
Who owns Zhejiang Cheng Yi Pharmaceutical Co Ltd
- Insiders 39.31%
- Institutions 1.46%
- Public & others 59.23%
- Shares outstanding 458M
- Free float 217M
Zhejiang Cheng Yi Pharmaceutical Co Ltd company profile
- Company name
- Zhejiang Cheng Yi Pharmaceutical Co Ltd
- Ticker
- 603811.SHG
- ISIN
- CNE100002YC7
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 604
- Fiscal year end
- December
- Address
- Building 20, Shenhong Road, Shanghai, China, 201100
- Phone
- 86 21 3328 3397
- Website
- chengyipharma.com
About Zhejiang Cheng Yi Pharmaceutical Co Ltd
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. engages in the research, development, production, and sales of formulations and active pharmaceutical ingredients in China and internationally. The company offers glucosamine hydrochloride raw materials and preparations, gastrodin raw materials, ribavirin preparations raw materials, and sulfur dioxide raw materials. It also provides injections, food, capsules, tablets, traditional Chinese medicines, preparations, and intermediates; and joint-related drugs, diuretics and antihypertensive drugs, antiviral drugs, antitumor drugs, vitamins, and sedative and brain-boosting drugs, as well as other health products and medical instruments. The company was formerly known as Wenzhou No. 3 Pharmaceutical Factory and changed its name to Zhejiang Cheng Yi Pharmaceutical Co., Ltd. in April 2001. Zhejiang Cheng Yi Pharmaceutical Co., Ltd. was founded in 1966 and is based in Shanghai, China.
Zhejiang Cheng Yi Pharmaceutical Co Ltd management
7- Mr. Chunjian ZhaoGM & Director · born 1977
- Mr. Sun Zhan LuChief Financial Officer · born 1978
- Ms. Lina YanVice President of Sales · born 1978
- Ms. Ze Hui KeDeputy GM, Secretary of the Board & Director · born 1986
- Mr. Zhi Hong ZhangDeputy GM & Director · born 1969
- Mr. Zhi Dong LuDeputy General Manager · born 1974
- Hai Ping XuAccounting Supervisor